CHRONOS19 STUDY RECOGNIZED WITH THE AMERICAN SOCIETY OF HEMATOLOGY AWARD
The interim results of the observational study “Registry of Patients with Hematologic Disease and COVID-19 in Russia” will be presented at the 62nd annual meeting of the American Society of Hematology (ASH), which will be held on December 5-8 in a virtual format. A poster presentation is included in Session: 904. Outcomes Research — Non-Malignant Conditions.
The research was recognized with the Abstract Achievement Award, which supports select trainees with high-achieving annual meeting abstracts who are chosen to present their work at the ASH annual meeting. The abstract can be found at https://ash.confex.com/ash/2020/webprogram/Paper138504.html.
The Registry was initiated this June by the National Research Center for Hematology in cooperation with hematological clinics in Moscow and several regions all over Russia with the support of the RakFond. The main objectives of the study are to determine how serious coronavirus infection is for patients with&hematological disease and how COVID-19 affects the treatment outcomes in these patients. More than 300 patients are currently enrolled in the registry.
The study is ongoing, data collection is performed on the platform of RakFond’s partner, Enrollme.ru